Well, based on the BUB case, 'priced in' would be a 40% increase in SP. I think that in itself is way more than what the specifics of the deal justify, but I'm not Mr Market, I'm just Mr Me.
However, relative to that, a 10% increase seems on par given that A2's FDA application is also confirmed as being under review. I was sceptical whether theyd actually move on that, but I'm less sceptical that it'll be granted by the FDA.
Well, based on the BUB case, 'priced in' would be a 40% increase...
-
- There are more pages in this discussion • 104 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.71 |
Change
-0.060(1.04%) |
Mkt cap ! $4.134B | |||
| Open | High | Low | Value | Volume |
| $5.70 | $5.78 | $5.69 | $6.339M | 1.108M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | $5.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.72 | 1701 | 2 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| A2M (ASX) Chart |